The present invention relates to a Lactobacillus plantarum GB104 strain (accession number: KCTC 14107BP) and a composition comprising same as active ingredient for prevention or treatment of cancer. The Lactobacillus plantarum GB104 strain according to the present invention increases production of INF-γ and granzyme B and activates immune cells such as cytotoxic T cells and NK cells, thereby being able to ultimately inhibit the formation and growth of tumors. Therefore, a composition comprising the Lactobacillus plantarum GB104 strain of the present invention as an active ingredient increases immune activity in the body and thus can be effectively utilized for treatment of cancer diseases and is highly industrially applicable.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A23K 10/18 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires de micro-organismes vivants
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Disclosed is a composition containing a Lactobacillus fermentum strain, preferably a composition containing Lactobacillus fermentum GB-102 strain deposited with accession number KCTC 14105BP and natural killer cells, and the use of the strain for administration in combination with natural killer cells for the suppression of weight gain or the prevention and/or treatment of metabolic diseases, and the composition and the combination therapy have an effect of remarkably suppressing weight gain. The composition and the combination therapy can be easily used to control the body weight of a subject, and are useful in the fields of beauty, livestock, medicines, and the like, in particular, are useful in the fields of pharmaceutical compositions, food additives, health functional foods, and therapeutic agents for ameliorating, preventing and treating metabolic diseases including obesity.
Disclosed is a composition containing a Lactobacillus fermentum strain, preferably a composition containing Lactobacillus fermentum GB-102 strain deposited with accession number KCTC 14105BP and regulatory T cells, and the use of co-administration of the strain and regulatory T cells for the suppression of weight gain or the prevention and/or treatment of metabolic diseases. The composition and the combination therapy have an effect of remarkably suppressing weight gain. Therefore, the composition and the combination therapy can be easily used to control the body weight of a subject, and are useful in the fields of beauty, livestock, medicines, and the like, in particular, are useful in the fields of pharmaceutical compositions, food additives, health functional foods, and therapeutic agents for ameliorating, preventing and treating metabolic diseases.
Lactobacillus helveticus strain can be effectively used for the treatment and prevention of inflammatory disease, particularly inflammatory bowel disease.
Provided is a novel Lactobacillus Plantarum strain and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus Plantarum (Accession No. KCTC 14107BP) according to the present invention may inhibit fat accumulation in white adipose tissue, brown adipose tissue, and liver tissue. The Lactobacillus Plantarum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus Plantarum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. In addition, the Lactobacillus Plantarum strain may regulate a concentration of metabolic hormones in blood. Therefore, the Lactobacillus Plantarum strain may be usefully used to prevent or treat a metabolic disease.
Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23K 10/18 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires de micro-organismes vivants
7.
LACTOBACILLUS FERMENTUM STRAIN, AND COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES CONTAINING SAME
There is provided a novel Lactobacillus fermentum strain (Accession No. KCTC 14105BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation in white adipose tissue and increase anti-inflammatory cells. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. In addition, the Lactobacillus fermentum strain may regulate a concentration of metabolic hormones and adipokines in blood. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent and treat a metabolic disease such as obesity.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
Lactobacillus fermentumLactobacillus fermentumLactobacillus fermentum strain GB-102 deposited with accession No. KCTC 14105BP, and regulatory T cells; and a use of the strain and regulatory T cells in combination therapy for preventing and/or treating metabolic diseases. The composition and combination therapy according to the present invention exhibit a significant weight gain suppression effect. Thus, the composition and combination therapy according to the present invention can be easily used for controlling the weight of a subject, and can be effectively used in the fields of cosmetics, livestock, medicine, and the like, and in particular, can be effectively used in the fields of pharmaceutical compositions, food additives, health functional foods, and therapeutic agents for improving, preventing, and treating metabolic diseases.
Lactobacillus fermentumLactobacillus fermentumLactobacillus fermentum GB-102 strain deposited under accession number KCTC 14105BP, and natural killer cells; and a combination therapy use of the strain and natural killer cells for inhibiting weight gain or preventing and/or treating metabolic diseases. The composition and the combination therapy of the present invention exhibit a remarkable inhibitory effect on weight gain. Therefore, the composition and the combination therapy of the present invention can be easily used in regulating the weight of a subject, and thus can be effectively used in the cosmetic, livestock and medical fields and the like and, in particular, can be effectively used in the fields of pharmaceutical compositions, food additives, health functional foods, therapeutic agents and the like for alleviating, preventing and treating metabolic diseases including obesity.
The present invention relates to a Lactobacillus Plantarum GB104 strain (accession number: KCTC 14107BP) and a composition comprising same as active ingredient for prevention or treatment of cancer. The Lactobacillus plantarum GB104 strain according to the present invention increases production of INF-? and granzyme B and activates immune cells such as cytotoxic T cells and NK cells, thereby being able to ultimately inhibit the formation and growth of tumors. Therefore, a composition comprising the Lactobacillus plantarum GB104 strain of the present invention as an active ingredient increases immune activity in the body and thus can be effectively utilized for treatment of cancer diseases and is highly industrially applicable.
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
Lactobacillus Plantarum Lactobacillus Plantarum GB104 strain (accession number: KCTC 14107BP) and a composition comprising same as active ingredient for prevention or treatment of cancer. The Lactobacillus plantarum GB104 strain according to the present invention increases production of INF-γ and granzyme B and activates immune cells such as cytotoxic T cells and NK cells, thereby being able to ultimately inhibit the formation and growth of tumors. Therefore, a composition comprising the Lactobacillus plantarum GB104 strain of the present invention as an active ingredient increases immune activity in the body and thus can be effectively utilized for treatment of cancer diseases and is highly industrially applicable.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
12.
LACTOBACILLUS HELVETICUS STRAIN AND COMPOSITION CONTAINING SAME FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES
Lactobacillus HelveticusLactobacillus Helveticus strain (accession number: KCTC 14110BP) of the present invention alleviates symptoms, such as a weight loss and an intestinal length reduction, of inflammatory bowel diseases, and has no side effects resulting from existing medications. Therefore, the Lactobacillus Helveticus strain can be advantageously used in the treatment and prevention of inflammatory diseases, especially, inflammatory bowel disease.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
Provided is a novel Lactobacillus Fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus Fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus Fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus Fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus Fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus Fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
The present invention relates to a novel Lactobacillus fermentum strain (accession number: KCTC 14106BP), and a composition for preventing or treating metabolic diseases, comprising same. Lactobacillus fermentum of the present invention can inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissues, and can effectively inhibit fat accumulation in brown adipose tissues and liver tissues. The Lactobacillus fermentum strain exhibits the excellent effect of lowering blood glucose and, particularly, can reduce fasting blood glucose levels, and can effectively improve insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain can be effectively used in the prevention or treatment of metabolic diseases such as obesity.
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
There is provided a novel Lactobacillus fermentum strain (Accession No. KCTC 14105BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation in white adipose tissue and increase anti-inflammatory cells. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. In addition, the Lactobacillus fermentum strain may regulate a concentration of metabolic hormones and adipokines in blood. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent and treat a metabolic disease such as obesity.
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
The present invention relates to a Lactobacillus plantarum strain, and to a composition for preventing or treating metabolic diseases containing same. The Lactobacillus plantarum strain (accession number: KCTC 14107BP) according to the present invention may effectively inhibit fat accumulation in white adipose tissue, brown adipose tissue, and liver tissue. The Lactobacillus plantarum strain exhibits an excellent glycemic improvement effect, and particularly, may reduce the fasting blood glucose level. The Lactobacillus plantarum strain may improve glucose tolerance and increase insulin sensitivity, thereby effectively improving insulin resistance. In addition, the Lactobacillus plantarum strain may control metabolic hormone concentration in the blood. Therefore, the Lactobacillus plantarum strain may be useful for preventing or treating metabolic diseases.
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
The present invention relates to a novel Lactobacillus fermentum strain (accession number: KCTC 14105BP), and to a composition for preventing or treating metabolic diseases containing same. The Lactobacillus fermentum according to the present invention may inhibit fat accumulation in white adipose tissue and increase the amount of anti-inflammatory cells. The Lactobacillus fermentum strain exhibits an excellent glycemic improvement effect, and particularly, may reduce the fasting blood glucose level. The Lactobacillus fermentum strain may improve glucose tolerance and increase insulin sensitivity, thereby effectively improving insulin resistance. In addition, the Lactobacillus fermentum strain may control metabolic hormone and adipokine concentrations in the blood. Therefore, the Lactobacillus fermentum strain may be useful for preventing or treating metabolic diseases such as obesity.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
Lactobacillus plantarumLactobacillus plantarum strain (accession number: KCTC 14107BP) according to the present invention may effectively inhibit fat accumulation in white adipose tissue, brown adipose tissue, and liver tissue. The Lactobacillus plantarum strain exhibits an excellent glycemic improvement effect, and particularly, may reduce the fasting blood glucose level. The Lactobacillus plantarum strain may improve glucose tolerance and increase insulin sensitivity, thereby effectively improving insulin resistance. In addition, the Lactobacillus plantarum strain may control metabolic hormone concentration in the blood. Therefore, the Lactobacillus plantarum strain may be useful for preventing or treating metabolic diseases.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
19.
Pharmaceutical composition for preventing or treating metabolic diseases, comprising bacteroides acidifaciens as active ingredient
Bacteroides acidifaciens as an active ingredient. In addition, the present disclosure relates to a transformant expressing a lean phenotype, in which an Atg7 gene is deleted in dendritic cells.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 35/66 - Micro-organismes ou substances provenant de micro-organismes
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
Bacteroides acidifaciens as an active ingredient. In addition, the present disclosure relates to a transformant expressing a lean phenotype, in which an Atg7 gene is deleted in dendritic cells.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
brevets
